1. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias
by David Gómez-Almaguer, Manuel Solano-Genesta, Luz Tarín-Arzaga, José Luis Herrera-Garza, Olga Graciela Cantú-Rodríguez, César Homero Gutiérrez-Aguirre, and José Carlos Jaime-Pérez
Blood
Volume 116(23):
December 2, 2010
©2010 by American Society of Hematology

2. Relapse-free survival in ITP and AIHA patients after low-dose rituximab and alemtuzumab.
Relapse-free survival in ITP and AIHA patients after low-dose rituximab and alemtuzumab. Relapse-free survival was considered as the period of maintenance of the best response achieved (ie, CR or PR).
David Gómez-Almaguer et al. Blood 2010;116:
©2010 by American Society of Hematology